From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative

Lancet Gastroenterol Hepatol. 2021 Feb;6(2):88-89. doi: 10.1016/S2468-1253(20)30392-7.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / therapeutic use
  • COVID-19 / prevention & control
  • Gastrointestinal Agents / administration & dosage*
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Inflammatory Bowel Diseases / drug therapy*
  • Infliximab / administration & dosage*
  • Infliximab / therapeutic use
  • Infusions, Intravenous
  • Injections, Subcutaneous
  • Self Administration
  • United Kingdom

Substances

  • Antibodies, Monoclonal
  • CT-P13
  • Gastrointestinal Agents
  • Infliximab